These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15808449)

  • 1. Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors.
    Anandan SK; Ward JS; Brokx RD; Bray MR; Patel DV; Xiao XX
    Bioorg Med Chem Lett; 2005 Apr; 15(8):1969-72. PubMed ID: 15808449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
    Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
    Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
    Gu W; Nusinzon I; Smith RD; Horvath CM; Silverman RB
    Bioorg Med Chem; 2006 May; 14(10):3320-9. PubMed ID: 16434199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A series of novel, potent, and selective histone deacetylase inhibitors.
    Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential protein acetylation induced by novel histone deacetylase inhibitors.
    Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
    Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
    Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
    Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural biasing elements for in-cell histone deacetylase paralog selectivity.
    Wong JC; Hong R; Schreiber SL
    J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases.
    Nishino N; Jose B; Okamura S; Ebisusaki S; Kato T; Sumida Y; Yoshida M
    Org Lett; 2003 Dec; 5(26):5079-82. PubMed ID: 14682769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.
    Hanessian S; Vinci V; Auzzas L; Marzi M; Giannini G
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4784-7. PubMed ID: 16870438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors.
    Chen B; Petukhov PA; Jung M; Velena A; Eliseeva E; Dritschilo A; Kozikowski AP
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1389-92. PubMed ID: 15713393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
    Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
    Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
    ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
    Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
    Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.